Health Care & Life Sciences

lilly-research-2col.jpg

Eli Lilly making renewed push in biotech field, where it once pioneered

August 16, 2014
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.More.

FDA approves Eli Lilly's injectable diabetes drug

September 18, 2014
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.More.

Obamacare enrollment at 7.3 million people, official says

September 18, 2014
That’s a 9-percent reduction from the government’s May estimate of 8 million, which reflected only how many people had signed up, not how many had paid and were enrolled in the coverage.More.

Testosterone drugs need study on heart risks, FDA panel says

September 18, 2014
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.More.

Blogs

 

In Depth Report

BioCrossroads has stoked state's life sciences industry, but challenges remainRestricted Content

In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.More.

SPECIAL REPORT: Indiana companies charge into China

With economic growth in the United States sluggish, Indiana companies are joining the race to capitalize on the fast-growing Chinese economy—even as hundreds of millions of Chinese move into the middle class and adopt a Western-style thirst for goods and services.More.

Hospitals suffer from spiking bond interest rates, investment lossesRestricted Content

Indianapolis-area hospitals have suffered a double whammy of spiking interest rates on their bonds and heavy losses in their investment portfolios and are trying to save cash any way they can.More.

In Depth Reports

 
Sponsored by
ADVERTISEMENT
Subscribe to IBJ
ADVERTISEMENT